United Kingdom· GB-APID-42675811000001102
Opdualag 240mg/20ml / 80mg/20ml concentrate for solution for infusion vials
A nivolumab and relatlimab product containing nivolumab + relatlimab, registered in United Kingdom by Bristol-Myers Squibb Pharmaceuticals Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Nivolumab and relatlimab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FY02 (nivolumab and relatlimab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Nivolumab and relatlimab · ATC L01FY02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Nivolumab + Relatlimab
- Manufacturer
- Bristol-Myers Squibb Pharmaceuticals Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FY02
- ATC class
- Nivolumab and relatlimab
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin05012712800071
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nivolumab and relatlimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaOPDUALAGBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandOpdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
- CzechiaOPDUALAGBristol-Myers Squibb Pharma EEIG, Dublin
- SpainOPDUALAG 240 MG/80 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandOpdualagBristol-Myers Squibb Pharma EEIG
- FranceOPDUALAG 240 mg/80 mg, solution à diluer pour perfusionBRISTOL-MYERS SQUIBB / PFIZER EEIG (IRLANDE)
- IrelandOpdualag 240 mg/80 mg sterile concentrateBristol-Myers Squibb Pharma EEIG
- IcelandOpdualagBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Opdualag
- Liechtenstein · Opdualag
- Norway · Opdualag
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2f2acb4c-7ae5-4aa8-9d8d-2bf04d84b33b GET /v1/drugs/2f2acb4c-7ae5-4aa8-9d8d-2bf04d84b33b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42675811000001102",
"desc": "Opdualag 240mg/20ml / 80mg/20ml concentrate for solution for infusion vials (Bristol-Myers Squibb Pharmaceuticals Ltd)",
"form": "Solution for infusion",
"vpid": "42683911000001101",
"source": "dmd",
"vtm_id": "42682211000001104",
"strength": "4 mg",
"substance": "Nivolumab + Relatlimab",
"ingredient": "Relatlimab",
"supplier_code": "3145301000001104"
}See everything about nivolumab and relatlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.